Amnion as a surrogate tissue reporter of the effects of maternal preeclampsia on the fetus by Masako Suzuki et al.
RESEARCH Open Access
Amnion as a surrogate tissue reporter of
the effects of maternal preeclampsia on the
fetus
Masako Suzuki1* , Ryo Maekawa1,2, Nicole E. Patterson1, David M. Reynolds1, Brent R. Calder1, Sandra E. Reznik3,4,5,
Hye J. Heo5, Francine Hughes Einstein5 and John M. Greally1*
Abstract
Background: Preeclampsia, traditionally characterized by high blood pressure and proteinuria, is a common pregnancy
complication, which affects 2–8 % of all pregnancies. Although children born to women with preeclampsia have a higher
risk of hypertension in later life, the mechanism of this increased risk is unknown. DNA methylation is an epigenetic
modification that has been studied as a mediator of cellular memory of adverse exposures in utero. Since each cell type
in the body has a unique DNA profile, cell subtype composition is a major confounding factor in studies of tissues with
heterogeneous cell types. The best way to avoid this confounding effect is by using purified cell types. However, using
purified cell types in large cohort translational studies is difficult. The amnion, the inner layer of the fetal membranes of
the placenta, is derived from the epiblast and consists of two cell types, which are easy to isolate from the delivered
placenta. In this study, we demonstrate the value of using amnion samples for DNA methylation studies, revealing
distinctive patterns between fetuses exposed to proteinuria or hypertension and fetuses from normal pregnancies.
Results: We performed a genome-wide DNA methylation analysis, HpaII tiny fragment Enrichment by Ligation-mediated
PCR (HELP)-tagging, on 62 amnion samples from the placentas of uncomplicated, normal pregnancies and from those
with complications of preeclampsia or hypertension. Using a regression model approach, we found 123, 85, and 99 loci
with high-confidence hypertension-associated, proteinuria-associated, and hypertension- and proteinuria-associated DNA
methylation changes, respectively. A gene ontology analysis showed DNA methylation changes to be selecting genes
with different biological processes in exposure status. We also found that these differentially methylated regions overlap
loci previously reported as differentially methylated regions in preeclampsia.
Conclusions: Our findings support prior observations that preeclampsia is associated with changes of DNA methylation
near genes that have previously been found to be dysregulated in preeclampsia. We propose that amniotic membranes
represent a valuable surrogate fetal tissue on which to perform epigenome-wide association studies of adverse
intrauterine conditions.
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Background
Preeclampsia (PE) is a common and potentially serious
pregnancy-associated disorder traditionally characterized
by de novo maternal hypertension and proteinuria after
20 weeks of gestation [1]. The latest criteria for the def-
inition of PE published by the American Congress of
Obstetricians and Gynecologists (ACOG) have changed,
with proteinuria being no longer needed for diagnosis,
while patients without proteinuria but with new-onset
thrombocytopenia, impaired liver function, renal insuffi-
ciency, pulmonary edema, or visual or cerebral distur-
bances are now also diagnosed as having PE [2]. PE, as
traditionally defined, affects 2–8 % of all pregnancies
and is associated with an increased risk of preterm birth
[3]. In recent years, the incidence of PE has risen in the
USA [4, 5] and pregnancy-associated hypertension has
also become more common [6], which may be attribut-
able to the increased prevalence of predisposing disor-
ders, including chronic hypertension, diabetes, and
obesity [7–9]. Not only does PE involve short-term risks
to the mother and fetus but children who were exposed
to PE in utero have an increased risk of diabetes mellitus
(meta-analysis from 16 studies [10]) and higher systolic
blood pressure during childhood and young adult life
[11–13]. A large population-based cohort study looked
at these delayed effects in more detail and showed that
children born at term who were exposed to PE were
more often hospitalized and had an increased risk of a
variety of illnesses, such as endocrine, nutritional, and
metabolic diseases throughout childhood and young
adult life [14]. These findings suggest that maternal PE
somehow causes a detrimental cellular “memory” in the
exposed offspring.
The mechanism by which PE causes the exposed fetus to
have increased risk of diseases later in life remains un-
known [14]. The potential for heritable epigenetic mecha-
nisms to propagate a cellular memory of early life
exposures [15–18] makes the molecular mediators of epi-
genetic regulation strong candidates for mediating the
long-term risk to individuals born to mothers with PE, a
potentially valuable mechanistic insight. Furthermore, as
maternal PE is not deterministic of adult disease in the ex-
posed infants but instead raises relative risk, any potential
method to define those individuals at greater risk based on
identifying and testing for distinctive epigenetic regulatory
marks in accessible cells would be of major value.
Epigenetic memory is believed to be mediated or
reflected by chemical modifications of genomic DNA and
possibly also chromatin states (reviewed in [19, 20]). DNA
methylation is a well-studied transcriptional regulator with
heritable epigenetic properties, involving the covalent
addition of a methyl group at the 5-carbon position of the
cytosine ring. Most DNA methylation occurs at the cyto-
sine of CpG dinucleotides, with 60–80 % of CpG sites
methylated in fully differentiated tissues and cells in mam-
mals (reviewed in [21]). During replication, the DNA
methylation status is propagated by DNA methyltransfer-
ases to daughter chromatids (reviewed in [22]). The
changes in DNA methylation that are associated with tran-
scriptional alterations are increasingly recognized to occur
at cis-regulatory loci that can be distant from gene pro-
moters and are very diversely located in different cell types
[23, 24]. As a consequence, genome-wide DNA methylation
studies that test as many cis-regulatory loci as possible are
best positioned to find alterations associated with human
diseases [25].
Testing the association between phenotypes and DNA
methylation profiles genome-wide (epigenome-wide associ-
ation studies (EWAS)) is increasingly common [26]. How-
ever, EWAS are frequently designed without taking into
account major influences on DNA methylation such as
genetic variation [27–31], cell subtype composition vari-
ation between samples [32, 33], and technical or batch ef-
fects [34]. A further problem in human studies is that it is
often not possible to access the cell type mediating the dis-
ease, instead requiring the use of surrogate tissues or cells.
Peripheral blood leukocytes have been used as an accessible
surrogate tissue in many EWAS, providing an excellent
paradigm for cell subtype variability influencing DNA
methylation [33, 35]. To reduce this source of bias in an
EWAS, a homogeneous cell type is ideally used, or the ap-
plication of an analytical approach that allows this source
of variability to be addressed [26, 32]. For research into pos-
sible epigenetic dysregulation in PE, non-invasive tissue
sampling from the neonate exposed to the intrauterine
stress is required. If large cohorts of subjects are needed to
power these studies [26], it is necessary to define a tissue
type that can be easily and uniformly sampled across mul-
tiple research groups and institutions.
The amnion is derived from the fetal side of the amnio-
chorionic membrane and shares a common embryological
origin with the fetus at the implantation stage. The placen-
tal side of the amniochorionic membrane, the chorion, is
derived from the trophectoderm. Amnion cells exhibit
pluripotent stem cell-like plasticity and can be differenti-
ated into cells expressing markers of mesodermal, endoder-
mal, or ectodermal cells with engraftment or appropriate
stimulation by specific differentiation factors [36–38]. The
amnion is relatively homogenous in terms of cell compos-
ition (mainly epithelial with some mesenchymal stromal
cells) and is technically easy to isolate. We hypothesized
that these factors make the amnion potentially an excellent,
practical surrogate fetal tissue in which to test for epigen-
etic alterations in neonates.
To test whether epigenetic regulators in the amnion
are affected by maternal, we performed genome-wide
DNA methylation profiling on 62 amnion samples from
infants born to women with PE or hypertension,
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comparing these with samples from uncomplicated preg-
nancies, looking for changes recurrently associated with
PE exposure. We identified differentially methylated re-
gions between the epithelial and mesenchymal stromal
cells of the amnion, allowing us to adjust for the influ-
ence of variable cell subtype composition on the DNA
methylation patterns observed. Our studies support the
value of using the amnion as a focus for studies of ad-
verse intrauterine conditions affecting the fetus.
Results
Clinical characteristics of subjects
We show in Table 1 the clinical characteristics of the
subjects that we studied, presenting data as mean ±
standard deviation (SD) when appropriate. We used a t
test for continuous variables and Fisher’s exact test for
categorical variables when calculating significance of dif-
ferences between groups. No statistically significant dif-
ferences between groups for mother’s age at delivery, sex
of fetus, and self-reported ancestry were found. The ges-
tational age at delivery was earlier for offspring with
complications (PE) compared to those without complica-
tions (control) (p < 0.05). Although the differences in
gestational age were statistically significant, the medians
of each group were comparable (39.3, 39.2, and 39.0)
with most babies born at term (after 37 weeks). Maternal
maximum diastolic and systolic blood pressures were
also significantly higher in the pregnancy complication




Hypertension PE p value
N = 15 N = 11 N = 36
Diagnostic criteria Systolic blood pressure (max) 130 IQR 122–134 160 IQR 148–170 175.5 IQR 157–183
Diastolic blood pressure (max) 82 IQR 77–85 98 IQR 93–108 103 IQR 98–115.5
Proteinuria
Negative/trace 15 11 6
1+ 0 0 13
2+ 0 0 8
>3+ 0 0 9
Characteristics Maternal age (year, mean ± SD) 27.3 ± 3.3 26 ± 6.0 26.6 ± 6.1 0.8413
(Mother and fetus) Week of gestation (median) 39.3 IQR 39.1–40.2 39.2 IQR 37.4–39.5 39 IQR 37.4–39.4 0.0191
Weight at birth (g, mean ± SD) 3454.3 ± .96 3097.3 ± 606.8 2931.1 ± 767.3 0.0566
Race 0.58
Black 4 2 11
Hispanic 5 6 19
White 1 1 4
Other 3 2 1
Declined 2 0 1
Sex (male, n) 5 8 15 0.120
NSVD (n) 5 8 15 0.120
Primiparous (n) 3 6 24 0.016
Smoked (n) 0 0 2 0.999
History of PE (n) 0 2 5 0.242
Comorbidities (n) Anemia 4 1 5 0.502
(Mother) Asthma 1 3 5 0.419
Obese (BMI > 30) 4 4 17 0.401
GDM 1 0 7 0.289
Chronic hypertension 0 1 4 0.453
Migraines 1 2 3 0.607
Medication (n) Hypertensive drug prescribed 0 1 9 0.006
(Mother) MgSO4 administration 0 6 25 <0.0001
IQR interquartile range
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groups compared to controls, as expected (p < 0.001).
Primiparity, a risk factor for PE (reviewed in [39]), was
significantly higher in the PE group (p = 0.016). Maternal
history of PE, another well-known risk factor for PE, was
not significantly different among the groups (p = 0.24).
Overall, our cohort appears to have the characteristics
expected of a typical PE study population.
Genome-wide DNA methylation profiling in amnion
samples
The genome-wide DNA methylation profiles of the 62
amnion samples were evaluated using HpaII tiny frag-
ment Enrichment by Ligation-mediated PCR (HELP)-
tagging [40], which offers a better representation of dis-
tal cis-regulatory elements than other survey assays of
DNA methylation [25]. HELP-tagging utilizes the
methylation-sensitive restriction enzyme HpaII and its
methylation-insensitive isoschizomer MspI to test the
methylation status at HpaII sites, generating an angular
metric that results in accurate quantification of DNA
methylation at >1.8 million loci in the human genome
[40]. Technical verification was performed with bisulfite
amplicon-seq using the Fluidigm micro-fluidic amplifica-
tion system (mean Pearson correlation 0.78, interquartile
range −0.84 to −0.78; see Additional file 1 for detailed
methods, analysis, and graphical data representations).
This verification confirmed that the genome-wide data
were robust enough to allow interpretation. There are
several known confounding influences on genome-wide
DNA methylation assays, including technical/batch ef-
fects, DNA sequence variants, cell subtype composition
variability, and sex/age [26, 27]. We addressed technical
effects (batch effects) using ComBat, keeping group in-
formation (PE, hypertension, and control) as the out-
come of interest (see Additional file 1 for analysis). We
addressed the possibility of local DNA sequence poly-
morphism by eliminating loci from analysis where the
±28 bp flanking the HpaII site overlaps a known single
nucleotide polymorphism (SNP, dbSNP142). We further
eliminated from analysis HpaII sites where the MspI
control tag count was low (<4), or located on the sex
chromosomes or at a repetitive element (RepeatMasker
annotation http://www.repeatmasker.org/). These con-
servative measures left us with 654,051 HpaII sites for
analysis.
Eliminating cell subtype composition effects
Although the amnion is less heterogeneous in terms of cell
subtypes than the other parts of the placenta, it consists of
two morphologically distinct cell types, amniotic epithelial
(AE) and amniotic stromal (AS) cells. We purified these
two cell types from amnion samples from four individuals
and performed whole-genome bisulfite sequencing of each
of the ten samples (including replicates), identifying
differentially methylated regions using Fisher’s exact test
[41]. As we expected, DNA methylation profiles showed
cell type-specific patterns. We identified three strongly dif-
ferentially methylated HpaII sites, Hpa_1553647,
Hpa_210409, and Hpa_621984 (Additional file 2: Figure
S1). Hpa_1553647 is located in the intron of the signal-
induced proliferation-associated 1-like 1 (SIPA1L1) gene.
SIPA1L1 encodes a protein that stimulates the Rap GTPase
activity [42] and has been identified as a human papilloma-
virus E6 targeted protein [43]. As there is no transcript re-
ported within 50 kb of Hpa_210409, we are unable to
speculate about the function of this locus. Hpa_621984 is
located in the intron of polo-like kinase 2 (PLK2) gene,
which is associated with cell cycle functions [44]. We
hypothesized that DNA methylation variability at these
differentially methylated sites could be associated with vari-
ability at multiple sites across samples, reflecting differences
in proportions of AE to AS cells in different samples. We
also tested whether any of these loci had DNA methylation
changes associated with the clinical phenotypes being
studied. We found Hpa_621984 to have only a weak
association with DNA methylation variability (p = 0.866,
Additional file 3: Table S1) and a strong association be-
tween Hpa_210409 and proteinuria (p = 0.008892). The
remaining HpaII_1553647 locus was therefore used as the
most robust indicator of cell subtype proportions. We re-
moved all HpaII sites which showed strong correlations
with HpaII_1553647 (r > 0.3, Spearman’s correlation). This
left 545,961 HpaII sites to test the DNA methylation
changes specific to PE exposure.
Using this high-confidence data set, we tested the degree
of contribution of known clinical covariates to DNA methy-
lation profiles using principal components analysis (PCA,
Fig. 1). We observed a significant contribution of protein-
uria (p = 0.0305) and a strong contribution of maximum
systolic blood pressure and magnesium sulfate treatment
(p = 0.157 and 0.160, respectively) to the DNA methylation
variability in our study. Magnesium sulfate has been used
for preventing seizures in women with PE. These results
suggested that there are PE exposure-specific DNA methy-
lation changes in the amnion.
Transcriptional studies of the amnion reveal expression
level changes of genes previously implicated in PE
Transcription and DNA methylation are potentially associ-
ated [45–47], prompting our exploration of this relationship
in our study. We performed directional RNA-seq on 12
without complication (control) and 17 PE amnion samples
(Additional file 1, detailed method with technical verifica-
tion and analysis). We found 41 high-confidence differen-
tially expressed genes between the PE and control amnions,
a list including genes previously associated with PE (fms-
like tyrosine kinase 1 (FLT1) [48, 49], S100 calcium binding
protein A8/A9 (S100A8/A9) [50, 51], pregnancy-associated
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plasma protein A2 (PAPPA2) [52], and C-X-C motif chemo-
kine (CXCL8) [53, 54] (Additional file 3: Table S2,
Additional file 4: Figure S2). Soluble FLT1 (sFLT1) is a well-
known anti-angiogenic factor which has been found to in-
crease in expression in PE (reviewed in [39]) with animal
models indicating that its over-expression leads to PE-like
symptoms [48]. S100A8 and CXCL8 are known
inflammation-related genes; S100A8 has been reported to
have increased expression levels in amnion samples from
mothers with PE and inflammation [55]. Up-regulation of
CXCL8 was also reported to be part of the response to pro-
inflammatory cytokines in first trimester decidual cells [56].
Macintire et al. reported that PAPPA2 expression is in-
creased in severe early-onset PE and is upregulated with
hypoxia [52]. Both inflammation and hypoxia are known
contributors to PE [57–61]. We did not, however, observe
local DNA methylation alterations in proximity to these dif-
ferentially expressed genes in our study (Additional file 4:
Figure S2), suggesting either that DNA methylation is not
involved in the regulation of these genes or that the regula-
tion occurs at CG dinucleotides that were not tested using
HELP-tagging.
Defining loci of differential DNA methylation attributable
to PE exposure
To identify DNA methylation changes associated with
PE exposure, we used a linear modeling approach. The
PCA results suggested that maximum systolic blood
pressure and proteinuria grade were strong contributors
to DNA methylation changes. We therefore ran three re-
gression models and measured the proportion of vari-
ance explained from each: model 1, testing the effect of
maximum systolic blood pressure; model 2, the effect of
proteinuria grade; and model 3, the combination of
both. We used ANOVA to test the significance of the
DNA methylation changes in each model. We further
applied a stringent threshold (false discovery rate (FDR)-
adjusted p values of <0.05 and differences between PE















































































Fig. 1 Biological and technical confounders contribute to DNA methylation value variations. The heatmap displays significant correlations for
each covariate. The –log10 p values of the linear regressions of the top ten principal components onto each known covariate are shown. The
color key shows corresponding numeric values, with darker color indicating increased significance. Proteinuria, maximum systolic blood pressure,
and magnesium sulfate treatment are contributing to the DNA methylation variability
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and control >10) and identified 123, 85, and 99 high-
confidence differentially methylated HpaII (DM-HpaII)
sites for each of the three models, respectively
(Additional file 3: Table S3). In Fig. 2a, we show the
overlap of DM-HpaII sites between the models. As
would be expected, we found DM-HpaII sites to overlap
between the combined model 3 and the individual
models 1 and 2. Gene ontology analysis showed distinct
patterns of enrichment for biological processes between
models. Cell-cell adhesion- and recognition-related and
carbohydrate metabolic-related genes were enriched in
model 2, while GTP-associated genes were enriched in
model 1 (Fig. 2b). This suggests that exposures of mater-
nal hypertension and proteinuria have different target
genes and biological consequences.
There are several DNA methylation analysis studies on
PE patients. A search of the PubMed database with the
terms “preeclampsia”/“pre-eclampsia,” “DNA methyla-
tion,” and “genome-wide”/“genome wide” finds 12 publi-
cations [62–73], of which two entries did not perform
genome-wide DNA methylation studies and one did not
study PE. Most studies were focused on the etiology of
PE; hence, most of the studies were performed on
trophectoderm-derived (placenta) or maternal blood
cells or a trophectoderm and epiblast mixed population
(chorionic membrane). One study used an epiblast-
derived tissue (cord blood cells) [63] and reported a list
of 319 genes as PE and gestational age-associated, differ-
entially methylated genes using Illumina Infinium
HumanMethylation450 BeadChip arrays. Because of the
platform difference, we are not able to compare system-
atically the individual CpG sites. A small number
(GABBR1, HMHA, TSPAN18, CACNA2D3, and SKI) of
the 319 genes were also found to be differentially meth-
ylated in our current study.
Seven DM-HpaIIs overlapped probes of the Illumina Infi-
nium HumanMethylation450 BeadChip. Of these, six have
been associated with aging [74, 75], obesity [76], osteoarth-
ritis [77], and liver development [78] (Additional file 3:
Table S4). A CpG site (Hpa_1775280/cg04521626) was re-
ported to be differentially methylated in two different stud-
ies using cord blood samples studying birth weight and
gestational age [79, 80]. Although Hpa_1775280/
cg04521626 did not show significant association on our
regression models, we observed significant associations be-
tween DNA methylation at this locus with birth weight and
with week of gestation (p = 0.00814 and p = 0.00046,
respectively).
Preeclampsia (PE) can be categorized based on the
time of onset, as early onset (EOPE) or late onset
(LOPE). While some clinical features overlap between
EOPE and LOPE, it has been reported that the etiologies
of disease, biomarkers, and maternal and fetus outcome
are different between EOPE and LOPE (reviewed in
[81]). Furthermore, the severities of hypertension and
proteinuria differ between patients. This suggests that
the degree of DNA methylation alterations may also vary
among the PE-exposed fetuses. Therefore, we searched
for CpG sites where DNA methylation variation within
groups is significantly higher in the PE-exposed than
that in control fetuses. We compared the variances of
each HpaII site in the controls and PE-exposed fetuses
with the F test (R project, stats package) and found 4058
variable HpaII (var-HpaII) sites in 3035 genes between
the control and PE (FDR-adjusted p value <10−7 and the
ratio of variance >20) (Additional file 3: Table S5). Of
those, 28 genes had more than 5 var-HpaII sites, and
several of those have been reported the association with
PE (PTPRN2, KCNMA1, and NFATC1), hypertension
(SDK1), and placental development (SALL3) (Additional
file 3: Table S6). We verified the increased variability of
DNA methylation predicted by HELP-tagging results
using bisulfite MassArray (Additional file 5: Figure S3
and Additional file 6: Figure S4).
Discussion
While the amnion is not part of the fetal soma and can-
not mediate the long-term PE effects on disease risk,
our hypothesis was that it provides an easily accessible
surrogate cell type reflecting fetal cell exposure to the
intrauterine stress of PE. The effects of PE on fetal cells
are not deterministic but instead influence the relative
risk of developing long-term disease phenotypes. In this
study, we showed that PE exposure-associated differen-
tially and variably methylated genes overlap with previ-
ously reported PE-associated differentially methylated
genes in studies of other tissue types. Our results sup-
port the use of the amnion as surrogate tissue in studies
of PE and other adverse intrauterine conditions. The
amnion membrane consists only two cell types: AE and
AS cells. Since each cell type has a unique DNA methy-
lation profile, variability in cell subtype composition be-
tween samples can be a strong confounding factor when
testing DNA methylation variability between samples.
Our identification of differentially methylated loci be-
tween the two cell types of the amnion allows us to
apply an approach similar to Houseman et al. [82] to ad-
just for cell subtype proportional variability, increasing
the interpretability of data derived from studies of the
amnion. The amnion is therefore a promising surrogate
tissue for studies of PE and potentially other intrauterine
stresses, as it is easy to collect, composed of only two
cell types whose proportions can be reported by differ-
entially methylated regions that we have identified, and
shows DNA methylation changes similar to those found
in other studies of cells of fetuses exposed to PE.
This study is the largest to date in terms of numbers
of individuals studied using genome-wide DNA
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Fig. 2 (See legend on next page.)
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methylation assays in PE (62 samples in total). Despite
this, we recognize that a larger cohort would be needed
to detect smaller changes in DNA methylation with con-
fidence, and we have not been able to account for the ef-
fects of DNA sequence variants on DNA methylation,
methylation quantitative trait loci (meQTLs) [30, 31, 83,
84]. Furthermore, while we adjusted for epithelial/stro-
mal proportions, we only used a single high-confidence
DMR for this analysis. Additionally, although we col-
lected samples from the placenta whose mother was not
diagnosed with chorioamnionitis or other inflammatory
disorder in this study, we cannot ignore the possibility of
occasional maternal cell contamination. Finally, the ~2
million loci tested using HELP-tagging only represent a
subset of CpG dinucleotides in the human genome,
which is likely to miss the majority of distal cis-regula-
tory elements [25]. A future, more definitive study would
have to be more comprehensive, adding genotyping and
cell types and using a larger cohort. A focus on the am-
nion would facilitate such an expanded study as it is very
easy to dissect from the delivered placenta, facilitating a
standardized sample collection in a multicenter project.
The results of the current study indicate that the amnion
could potentially be the focus of research performed by
diverse groups interested in the effects of adverse intra-
uterine conditions, allowing integration of information
obtained among different investigators.
In this study, we identified 123, 85, and 99 high-
confidence differentially methylated HpaII (DM-HpaII)
sites for hypertension, proteinuria, and hypertension-
proteinuria regression models, respectively, and 4058
variable HpaII (var-HpaII) sites. These differences per-
sisted despite rigorous measures to account for variabil-
ity in cell subtype composition, potential DNA sequence
variation, and technical artifacts, with the technical per-
formance of the genome-wide assay verified with a
highly quantitative and orthogonal assay. A gene ontol-
ogy analysis showed DNA methylation (DM-HpaII)
changes to be selecting genes with different biological
processes in exposure status. Cell-cell adhesion- and
recognition-related and carbohydrate metabolic-related
genes were enriched in model 2 (proteinuria), while
GTPase-associated genes were enriched in model 1
(hypertension). This suggests a model of exposures to
maternal hypertension and maternal proteinuria affect-
ing different target genes, with distinct biological conse-
quences. The associations between PE exposure and
diabetes later in life have been identified in a couple of
large cohort studies [14, 85]. In addition, many molecu-
lar and cellular studies have identified the roles of
GTPase in the regulation of vascular smooth muscle cell
proliferation and migration (reviewed in [86]). While off-
spring outcomes after birth are not available from our
cohort, these alterations might conceivably be associated
with diseases later in life. It has been demonstrated that
NFATC1 induces COX-2 expression in a rat model [87].
Induction of COX-2 expression has been reported in
syncytiotrophoblast cells and systemic vascular tissue of
PE patients [88, 89], and COX-2 expression has been re-
lated to reduced blood flow in PE patients [89]. A mouse
model study reported that the SALL3 locus is a hotspot
of epigenetic alterations associated with placentomegaly
of cloned mice. They reported that the DNA methyla-
tion status at the SALL3 locus was associated with pla-
cental sizes of the animal [90]. It has been shown that
the size of the placenta in EOPE tends to small and that
this size is associated with the baby’s weight, while a U-
shaped placental size distribution was reported in preg-
nancies with LOPE [91]. It has been reported that low
placental weight at birth is associated with an increased
risk of hypertension of the offspring later in life [11, 13].
While further longitudinal studies are needed to test the
associations between epigenetic alterations in this locus
and the disease prevalence of the offspring, the epigen-
etic signature at the SALL3 locus might be a potential
risk predictor of later diseases of the offspring.
Conclusions
To our knowledge, this is the largest study to address
genome-wide DNA methylation changes in PE-exposed
babies with adjustment for cell composition variations.
Our findings support previous evidence that exposure to
PE changes methylation of the fetal DNA. The differen-
tially methylated genes and associated pathways we iden-
tified here are in line with those found in previous
studies testing the effect of PE on fetal epigenetic pro-
gramming. We propose amniotic membranes as the best
surrogate tissue to perform large-scale, epigenome-wide
association studies of intrauterine stresses.
Methods
Sample collection
Amnion samples were collected immediately after deliv-
ery from women with and without PE at Montefiore
Medical Center, the university hospital of the Albert
Einstein College of Medicine. To eliminate maternal
(See figure on previous page.)
Fig. 2 Differentially methylated HpaII (DM-HpaII) sites. a DM-HpaIIs common in between models, a Venn diagram showing the overlapping DM-HpaIIs
between models. b Exposures of maternal hypertension and proteinuria showed different target genes and biological process. The
heatmap displays the –log10 p values of gene ontology enrichment status (Enrichr, GO biological process). Distinct patterns of enrichment
for gene ontology biological processes between models were observed
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blood contamination, we gently washed the collected
membrane twice with 0.9 % NaCl and once with RNAla-
ter solution. Then the washed membrane samples were
temporarily stored in the RNAlater solution to protect
RNAs from nucleases, at 4 °C for up to 20 h, and then
the samples were cut into small pieces and stored at
−80 °C until use. Diagnosis of PE was defined as follows:
sustained systolic blood pressure of ≥140 mmHg or sus-
tained diastolic blood pressure of ≥90 mmHg on 2 sep-
arate readings; proteinuria measurement of 1+ or more
on a dipstick; or a 24-h urine protein collection with
300 mg in specimen or observed other PE clinical
characteristics. Women who did not have proteinuria or
other PE clinical characteristics but had increased blood
pressure (sustained systolic blood pressure of ≥140 mmHg
or sustained diastolic blood pressure of ≥90 mmHg on two
separate readings) were grouped as having with complica-
tion (hypertension). This study was approved by the Institu-
tional Review Board (IRB) for Human Research at Albert
Einstein College of Medicine, Bronx, NY.
Cell isolation and culture
To isolate fresh cells, the collected amnions or umbilical
cords were washed in 100 U/ml penicillin and 100 μg/ml
streptomycin-supplemented Dulbecco’s modified Eagle’s
medium (DMEM) at room temperature followed by imme-
diate cell isolation. For amniotic epithelial (AE) and amni-
otic stromal (AS) cells, we isolated five pairs of AE and AS
cells from the same individuals with series of digestions of
amnion membrane [92]. Isolated cells were snap-
frozen or maintained in a 1:1 mixture of Ham’s F-12
and DMEM supplemented with 10 % fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin.
DNA and RNA extraction
DNA samples were extracted with a standard phenol-
chloroform treatment method [40], and total RNA sam-
ples were extracted with TRIzol reagent.
Genome-wide DNA methylation assays
We evaluated genome-wide DNA methylation profiles in
amnion samples with our previously published opti-
mized tag-based DNA methylation assay (HELP-tagging)
[40]. One microgram of each sample was digested with
HpaII as a starting material. We used deeply sequenced
MspI libraries generated from commercially available
pooled human genomic DNA (Roche) for DNA methyla-
tion calculation. The degree of methylation was calcu-
lated using our previously reported angle transformation
method [40]. The results were verified using a bisulfite
treatment based micro-methylation-seq method (de-
tailed protocol and results shown in Additional file 7).
To identify a cell type-specific DNA methylation, we
used low-coverage whole-genome bisulfite sequencing,
selecting differentially methylated loci using Fisher’s
exact test (p < 0.00001). The obtained candidate HpaII
sites were verified using conventional bisulfite sequen-
cing or bisulfite MassArray.
Single locus DNA methylation assays
We performed single locus DNA methylation assays to as-
sess the DNA methylation status of candidate HpaII sites
we identified with genome-wide DNA methylation assays
using bisulfite MassArray [93]. We designed bisulfite
primers using MethPrimer (http://www.urogene.org/meth
primer/), testing the primer’s specificities with BiSearch
(http://bisearch.enzim.hu/) and the amplicon’s analyzability
with the amplicon prediction function of MassArray [93]
(Bioconductor, http://www.bioconductor.org/packages/re
lease/bioc/html/MassArray.html). The primer sequences
used in this study are listed in Additional file 8. Five hun-
dred nanograms of genomic DNA was treated with sodium
bisulfite using the EZ DNA Methylation Gold Kit (Zymo
Research). Bisulfite-treated DNA samples were used as a
template for PCR amplification using the following condi-
tion: 2.5 μl of 10x PCR buffer, 1 μl of 20 μM each primer,
0.5 μl of 10 mM dNTP mix, FastStart HiFi polymerase, and
10 ng of template (as starting material) in a final volume of
25 μl; 95 °C for 10 min, then 42 cycles of 95 °C for 30 s, an-
nealing temperatures for 30 s and 74 °C for 30 s followed
by 10 min at 74 °C for the final extension.
Directional RNA-seq
The transcription profiles were defined using directional
RNA-seq. We used 500 ng of total RNA as starting mater-
ial. Before reverse transcription, the ribosomal RNAs were
depleted with Ribo-Zero rRNA removal kit (Epicentre).
The reverse transcription was performed using the Super-
Script III First-Strand Synthesis System followed by second
strand cDNA synthesis with deoxyuridine triphosphates
(dUTPs). Synthesized double-stranded cDNAs were
fragmented with Covaris (200–300 bp as target length),
end-repaired, dA tailed and adapters added for the Illumina
sequencer. To maintain the directional information, we
used a combination of dUTP incorporation and uracil-
DNA glycosylase [94]. All libraries were quality-checked be-
fore the sequence and sequenced on Illumina HiSeq 2500
(100 bp single-end reads). The verification of directional
RNA-seq was performed with quantitative RT-PCR. The
detailed protocol and the verification results are shown in
Additional file 7.
Bioinformatic analyses
All bioinformatics analyses we used here were per-
formed on a high-performance computing cluster of
Albert Einstein College of Medicine. We used the fol-
lowing packages: FASTQC, Trim_Galore (http://
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lore/), bismark [95], samtools [96], bedtools (http://
bedtools.readthedocs.org/en/latest/#), STAR [97],
HTseq-count [98], and R version 3.2.1 (http://www.r-




All the codes used in this study are listed in Additional
file 7 and are publicly available at our GitHub server:
https://github.com/GreallyLab/PE_Suzuki_et_al_2016.
Additional files
Additional file 1: We described the study design, detailed analytical
methods, and verification results in the supporting information file.
(DOCX 21.2 MB)
Additional file 2: Figure S1. Cell type-specific DNA methylation. A)
Bisulfite sequencing results of Hpa_1553647. Each row represents the
sequence result from bisulfite PCR products. We show four amnion, four
amniotic epithelial cell, and amniotic stromal cell results. The amniotic
epithelial and stromal cells were isolated from four individuals. The blue
arrow indicates the Hpa_1553647 position in the sequencing results. B)
Bisulfite MassArray results of Hpa_210409 and Hpa_621984. The y-axis
shows the % DNA methylation in amniotic epithelial and amniotic
stromal cells (from four individuals). The p values were calculated by a
t test. The error bars indicate the standard deviations. (PDF 317 kb)
Additional file 3: Table S1. Lists of p values of principal component
analysis with known covariates. Table S2. A list of differentially expressed
genes. Table S3. Lists of differentially methylated HpaII sites in each
model. Table S4. A list of differentially methylated HpaII sites with
previously reported Infinium HumanMethylation450 BeadChip
differentially methylated probes. Table S5. A list of variably methylated
HpaIIs. Table S6. A list of var-HpaII sites harboring genes. (XLSX 374 kb)
Additional file 4: Figure S2. Differentially expressed genes in
preeclampsia-exposed amnion. A MA plot shows the distribution of
differentially expressed and differentially methylated genes. The x-axis
shows counts per million (CPM), and the y-axis shows log-fold changes.
The differentially methylated genes are highlighted in red and the
differentially expressed genes are highlighted in green. (PDF 4.30 MB)
Additional file 5: Figure S3. Genes with local variable HpaII sites. HpaII
sites with variable DNA methylation are shown at specific loci with HELP-
tagging (angle values = (1 − DNA methylation value)) and corresponding
bisulfite MassArray verification results. The var-HpaII track indicates loci
that could be analyzed by bisulfite MassArray in red, and those that could
not be analyzed in gray (PCR amplification problem or more than 2 CpG
sites in a MassArray fragment). The blue loci are those in which the
analysis of the amplicon indicated the likely presence of a sequence
polymorphism [93]. Top panel: SALL3 region, bottom panel: KCNMA1 re-
gion. (PDF 1.33 MB)
Additional file 6: Figure S4. Comparison of the DNA methylation
distribution of variable HpaII sites. The distributions of the DNA methylation
levels of variable methylation sites in severe PE-exposed (PE_S, green) (protein-
uria grade ≥3 and systolic blood pressure ≥160 mmHg), less severe
PE-exposed (PE_M, orange) (proteinuria grade ≤1 and systolic blood
pressure≥ 140 mmHg) and control (blue) were summarized graphically in
violin plots. (PDF 895 kb)
Additional file 7: Codes used in this study. (TXT 66.7 kb)
Additional file 8: Supporting Tables. (XLSX 15.7 MB)
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